[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343173-105":59,"doc-detail-343173-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-a-novel-tki-anlotinib-for-the-treatment-of-advanced-digestive-system-neoplasms-a-systematic-review-and-meta-analysis","Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms - a systematic review and meta-analysis","","Systematic review evaluates anlotinib targeted therapy for advanced digestive system neoplasms (DSNs) by extracting clinical trials from PubMed, Cochrane Library, Web of Science, Embase, CNKI, and Wanfang up to October 2023. Outcomes include therapeutic efficacy, quality of life (QOL), and adverse events. Twenty trials with 1,613 patients show that combining anlotinib with conventional treatment improves 6-month overall survival, overall response, and disease control rate versus conventional treatment alone. Benefits come with higher incidences of several adverse events, while some other events are not significantly different.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-a-novel-tki-anlotinib-for-the-treatment-of-advanced-digestive-system-neoplasms-a-systematic-review-and-meta-analysis/343173/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-a-novel-tki-anlotinib-for-the-treatment-of-advanced-digestive-system-neoplasms-a-systematic-review-and-meta-analysis/343173.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the systematic review?","Question",{"text":112,"@type":113},"To systematically evaluate the efficacy and safety of anlotinib targeted therapy for patients with advanced digestive system neoplasms (DSNs).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases were searched and what timeframe was used?",{"text":117,"@type":113},"Clinical trials were extracted from PubMed, the Cochrane Library, Web of Science, Embase, CNKI, and Wanfang up to October 2023.",{"name":119,"@type":110,"acceptedAnswer":120},"How does anlotinib plus conventional treatment compare with conventional treatment alone?",{"text":121,"@type":113},"The combination significantly improves 6-month overall survival, overall response, and disease control rate, but increases the rates of several adverse events such as hypertension and proteinuria.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343173,1790445525,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Systematic Review PUBLISHED 14 August 2024  \nDOI 10.3389/fimmu.2024.1393404  \nOPEN ACCESS  \nEDITED BY  \nSubhash Kumar Tripathi,  \nSeattle Children’s Research Institute, United States  \nREVIEWED BY  \nMohammad Imran K. Khan, Columbia University, United States Mohd Wajid Ali Khan,  \nUniversity of Hail, Saudi Arabia  \n*CORRESPONDENCE Min Meng  \n [mengmin2011@126.com](mengmin2011@126.com)[ ](mengmin2011@126.com)Ying Mu  \n [muying_xiaohua@163.com](muying_xiaohua@163.com)  \nRECEIVED 29 February 2024  \nACCEPTED 29 July 2024  \nPUBLISHED 14 August 2024  \nCITATION  \nZhou C, Wang W, Mu Y and Meng M (2024) Efﬁcacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis.  \nFront. Immunol. 15:1393404 .  \ndoi: 10.3389/fimmu.2024.1393404  \nCOPYRIGHT  \n© 2024 Zhou, Wang, Mu and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEfﬁcacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis  \nChanghui Zhou 1, Weihua Wang 1, Ying Mu 2* and Min Meng 1*  \n1 Department of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, Shandong, China, 2 Department of Gastroenterology, Liaocheng People’s Hospital, Liaocheng, Shandong, China  \nObjective: To systematically evaluate the efﬁcacy and safety of anlotinib targeted therapy for the treatment of patients with advanced digestive system neoplasms (DSNs) .  \nMethods: Clinical trials were extracted from PubMed, the Cochrane Library, Web of Science, Embase, China National Knowledge Infrastructure (CNKI) and the Wanfang database up to October 2023 . Outcome measures, including therapeutic efﬁcacy, quality of life (QOL) and adverse events, were extracted and evaluated.  \nResults: Twenty trials, including 1,613 advanced DSNs patients, were included. The results indicated that, compared with conventional treatment alone, the combination of anlotinib targeted therapy with conventional treatment signiﬁcantly improved the patients ’ 6-months overall survival (OS, OR=1 .76, CI=1 . 53 to 2 . 02, P\u003C0 . 00001), overall response (ORR, OR=1 .76, CI=1 . 53 to 2 . 02, P\u003C0.00001) and disease control rate (DCR, OR=1.51, 95% CI=1.25 to 1.84, P\u003C0 . 0001) . Moreover, the group that received the combined therapy had higher rates of hypertension (P\u003C0.00001), proteinuria (P\u003C0.00001), fatigue (P\u003C0.00001), diarrhea (P\u003C0.00001), hypertriglyceridemia (P=0.02), alanine aminotransfease (ALT)increased (P=0.004), aspartate transaminase (AST) increased (P=0.006), anorexia (P\u003C0.00001), weight loss (P=0.002), abdominal pain (P=0 . 0006), hypothyroidism (P=0 . 02), prolonged QT interval (P=0 . 04) . Analyses of other adverse events, such as gastrointestinal reaction, leukopenia, and neutropenia, did not reveal signiﬁcant differences (P>0 . 05) .  \nConclusion: The combination of anlotinib targeted therapy and conventional treatment is more effective for DSNs treatment than conventional treatment alone . However, this combined treatment could lead to greater rates of hypertension, albuminuria and hand-foot syndrome. Therefore, the beneﬁtsand risks should be considered before treatment.  \nKEYWORDS  \nanlotinib, target therapy, conventional treatment, digestive system neoplasms, meta-analysis  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nDigestive system neoplasms (DSNs) are an important part of the incidence and mortality rate of cancer in the world, and cause 3,524,932 deaths in 2020, which accounts for 18% of all cancer deaths worldwide (1–3). ","cbCaijw6sLM63EBV","https://ap.wps.com/l/cbCaijw6sLM63EBV","pdf",3628214,15,"English","# Introduction\n## Rationale for targeted therapy in advanced DSNs\n# Methods\n## Study sources and extracted outcomes\n# Results\n## Efficacy outcomes\n## Adverse events and tolerability\n# Conclusion","[{\"question\":\"What is the main objective of the systematic review?\",\"answer\":\"To systematically evaluate the efficacy and safety of anlotinib targeted therapy for patients with advanced digestive system neoplasms (DSNs).\"},{\"question\":\"Which databases were searched and what timeframe was used?\",\"answer\":\"Clinical trials were extracted from PubMed, the Cochrane Library, Web of Science, Embase, CNKI, and Wanfang up to October 2023.\"},{\"question\":\"How does anlotinib plus conventional treatment compare with conventional treatment alone?\",\"answer\":\"The combination significantly improves 6-month overall survival, overall response, and disease control rate, but increases the rates of several adverse events such as hypertension and proteinuria.\"}]","Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms - a systematic review and meta-analysis | PDF",1790050179,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fad5d503d6d9cf7c79df89219e3304f6.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd7c45b1d533a61ec53bf0534d3b0b05.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63fa66def90f5d0a30441c586fca377f.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ad68ef569be88319047d18f22155fd9.webp",980,1385]